| __timestamp | Dyne Therapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 14400000 |
| Thursday, January 1, 2015 | 2028000000 | 33800000 |
| Friday, January 1, 2016 | 2281000000 | 35900000 |
| Sunday, January 1, 2017 | 2932000000 | 1254000 |
| Monday, January 1, 2018 | 24000 | 4889000 |
| Tuesday, January 1, 2019 | 271000 | 7400000 |
| Wednesday, January 1, 2020 | 700000 | 10100000 |
| Friday, January 1, 2021 | 1088000 | 14300000 |
| Saturday, January 1, 2022 | 3345000 | 23200000 |
| Sunday, January 1, 2023 | 2461000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial health is crucial. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and Dyne Therapeutics, Inc. over the past decade. Neurocrine Biosciences, a leader in neurological therapies, has shown a steady increase in its cost of revenue, peaking at nearly $40 million in 2023, a 175% rise from 2014. In contrast, Dyne Therapeutics, specializing in muscle disease treatments, experienced a dramatic fluctuation. After a peak in 2017, their costs plummeted by over 99% in 2018, reflecting strategic shifts or operational changes. This stark contrast highlights the diverse financial strategies within the biotech sector. As investors and stakeholders, understanding these trends can provide insights into company priorities and market positioning.
Cost of Revenue Comparison: Pfizer Inc. vs Dyne Therapeutics, Inc.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.